Show simple item record

dc.contributor.authorTutt, A
dc.contributor.authorCheang, M
dc.contributor.authorKilburn, L
dc.contributor.authorTovey, H
dc.contributor.authorGillett, C
dc.contributor.authorPinder, S
dc.contributor.authorLanchbury, J
dc.contributor.authorAbraham, J
dc.contributor.authorBarrett, S
dc.contributor.authorBarrett-Lee, P
dc.contributor.authorChan, S
dc.contributor.authorGazinska, P
dc.contributor.authorGrigoriadis, A
dc.contributor.authorKernaghan, S
dc.contributor.authorHoadley, K
dc.contributor.authorGutin, A
dc.contributor.authorHarper-Wynne, C
dc.contributor.authorHatton, M
dc.contributor.authorOwen, J
dc.contributor.authorParker, P
dc.contributor.authorRoylance, R
dc.contributor.authorShaw, A
dc.contributor.authorSmith, I
dc.contributor.authorThompson, R
dc.contributor.authorTimms, K
dc.contributor.authorWardley, Andrew M
dc.contributor.authorWilson, G
dc.contributor.authorHarries, M
dc.contributor.authorEllis, P
dc.contributor.authorAshworth, A
dc.contributor.authorPerou, C
dc.contributor.authorBliss, J
dc.contributor.authorRahman, N
dc.contributor.authorBrown, R
dc.date.accessioned2017-05-12T12:06:25Z
dc.date.available2017-05-12T12:06:25Z
dc.date.issued2017-02-14
dc.identifier.citationBRCA1 methylation status, silencing and treatment effect in the TNT trial: a randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer 2017, 77 (4 Supplement):S6-01 Cancer Researchen
dc.identifier.issn0008-5472
dc.identifier.issn1538-7445
dc.identifier.doi10.1158/1538-7445.SABCS16-S6-01
dc.identifier.urihttp://hdl.handle.net/10541/620342
dc.language.isoenen
dc.relation.urlhttp://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS16-S6-01en
dc.rightsArchived with thanks to Cancer Researchen
dc.titleBRCA1 methylation status, silencing and treatment effect in the TNT trial: a randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast canceren
dc.typeMeetings and Proceedingsen
dc.contributor.departmentInstitute of Cancer Research, Breast Cancer Now, London,en
dc.identifier.journalCancer Researchen


This item appears in the following Collection(s)

Show simple item record